Skip to main
CYRX

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort Inc. reported a total revenue of $44 million, reflecting a 15% year-over-year increase in constant currency, indicating a steady growth trajectory. The ongoing rise in gene therapy programs, particularly in oncology and rare diseases, suggests a robust market demand and an expanding pipeline of therapies, which could further enhance revenue in the coming quarters. The company is also positioned favorably as the life sciences industry grows increasingly comfortable with cell and gene therapies, which bodes well for increased commercial revenue and clinical trial activity.

Bears say

CryoPort Inc. is experiencing a concerning decline in the funding landscape for start-ups within the life sciences sector, with Series A and seed financing volumes decreasing quarter-over-quarter in 2Q:25, which could impact future growth prospects. Additionally, while the company reported a year-over-year growth in Life Sciences Services revenue, the deceleration from 21% to 16% indicates a potential trend of slowing revenue growth, compounded by anticipated headwinds in margins and profitability. Lastly, the adjustment to lower earnings per share forecasts for 2026 further underscores a negative outlook, reflecting challenges such as reduced demand for MVE freezers and fewer expected approvals in cell and gene therapy.

CryoPort (CYRX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Buy based on their latest research and market trends.

According to 9 analysts, CryoPort (CYRX) has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.